Cargando…
Glucagon‐like peptide‐1 receptor agonist regulates fat browning by altering the gut microbiota and ceramide metabolism
Studies have shown that antidiabetic drugs can alter the gut microbiota. The hypoglycemic effects of the drugs can be attributed in part to certain species in the gut microbiome that help the drugs work more effectively. In addition, increasing energy expenditure via the induction of adipose tissue...
Autores principales: | Lin, Ke, Dong, Chunyan, Zhao, Binyan, Zhou, Bailing, Yang, Li |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10661313/ https://www.ncbi.nlm.nih.gov/pubmed/38020719 http://dx.doi.org/10.1002/mco2.416 |
Ejemplares similares
-
A Glucagon-Like Peptide-1 Receptor Agonist Lowers Weight by Modulating the Structure of Gut Microbiota
por: Zhao, Li, et al.
Publicado: (2018) -
Regulation of glucagon‐like peptide‐1 sensitivity by gut microbiota dysbiosis
por: Yamane, Shunsuke, et al.
Publicado: (2017) -
Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
por: Lee, Seungah, et al.
Publicado: (2017) -
Neural effects of gut‐ and brain‐derived glucagon‐like peptide‐1 and its receptor agonist
por: Katsurada, Kenichi, et al.
Publicado: (2016) -
Brown Adipose Tissue: A New Potential Target for Glucagon-like Peptide 1 Receptor Agonists in the Treatment of Obesity
por: Hropot, Tim, et al.
Publicado: (2023)